Biochemical and clinical aspects of methotrexate neurotoxicity

Chemotherapy

Volumn 49, Issue 1-2, 2003, Pages 92-104

  Vezmar, Sandra ^a   Becker, Achim ^a   Bode, Udo ^a   Jaehde, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Adenosine; Biopterins; Cancer; CNS; Excitatory amino acids; Folates; Homocysteine; Methotrexate; Neurotoxicity

Indexed keywords

ADENOSINE; BIOPTERIN; EXCITATORY AMINO ACID; FOLIC ACID; FOLINIC ACID; HOMOCYSTEINE; METHOTREXATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE TOXICITY; AMNESIA; ARACHNOIDITIS; ASTROCYTOSIS; ATAXIA; BACKACHE; BLADDER DYSFUNCTION; BRAIN ATROPHY; BRAIN CALCIFICATION; BRAIN DISEASE; BRAIN NECROSIS; CHRONIC TOXICITY; COMA; CONFUSION; DEMENTIA; DEMYELINATION; DEPRESSION; DISORIENTATION; DRUG FATALITY; DRUG MEGADOSE; DRUG OVERDOSE; DYSPHASIA; FATIGUE; FEVER; FOLIC ACID DEFICIENCY; HEADACHE; HEMIPARESIS; HUMAN; INSOMNIA; IONIZING RADIATION; IRRITABILITY; LEARNING DISORDER; LEG PAIN; LEUKOENCEPHALOPATHY; METABOLIC DISORDER; MICROANGIOPATHY; MOOD DISORDER; NAUSEA; NEUROTOXICITY; NONHUMAN; PARAPLEGIA; PRIORITY JOURNAL; PSYCHOSIS; QUADRIPLEGIA; RADIATION INJURY; REVIEW; SEIZURE; SIDE EFFECT; SLURRED SPEECH; SPEECH DISORDER; SPINAL CORD DISEASE; VERTIGO; VISUAL DISORDER; VOMITING;

ACUTE DISEASE; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN; EXCITATORY AMINO ACIDS; HUMANS; METHOTREXATE; NEUROTOXICITY SYNDROMES; SPINAL CORD;

EID: 0037262627     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069773     Document Type: Review

References (130)

1. Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: A new classification. Cancer Treat Rep 1981;65 suppl 1:89-98.
2. Quinn CT, Kamen BA: A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Investig Med 1996;44:522-530.
3. Weiss HD, Walker MD, Wiernik PH: Neurotoxicity of commonly used antineoplastic agents. N Engl J Med 1974;291:127-133.
4. Kaplan RS, Wiernik PH: Neurotoxicity of antineoplastic drugs. Semin Oncol 1982;9:103-130.
5. Tuxen MK, Hansen SW: Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 1994;20:191-214.
6. Geiser CF, Bishop Y, Jaffe N, Furman L, Traggis D, Frei E, III: Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 1975;45:189-195.
7. Bleyer AW: Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 1977;61:1419-1425.
8. Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973;289:770-773.
9. Allen JC, Rosen G: Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma. Ann Neurol 1978;3:441-444.
10. Walker RW, Allen JC, Rosen G, Caparros B: Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986;4:1845-1850.
11. Yim YS, Mahoney DH, Jr, Oshman DG: Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 1991;67:2058-2061.
12. Gagliano RG, Costanzi JJ: Paraplegia following intrathecal methotrexate: Report of a case and review of the literature. Cancer 1976;37:1663-1668.
13. Keime-Guibert F, Napolitano M, Delattre JY: Neurological complications of radiotherapy and chemotherapy. J Neurol 1998;245:695-708.
14. Garcia-Tena J, Lopez-Andreu JA, Ferris J, Menor F, Mulas F, Millet E, et al: Intrathecal chemotherapy-related myeloencephalopathy in a young child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1995;12:377-385.
15. Watterson J, Toogood I, Nieder M, Morse M, Frierdich S, Lee Y, et al: Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 1994;74:3034-3041.
16. Jaffe N, Takaue Y, Anzai T, Robertson R: Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer 1985;56:1356-1360.
17. Kay HE, Knapton PJ, O'Sullivan JP, Wells DG, Harris RF, Innes EM, et al: Encephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child 1972;47:344-354.
18. Allen JC, Rosen G, Mehta BM, Horten B: Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 1980;64:1261-1273.
19. Shapiro WR, Chernik NL, Posner JB: Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch Neurol 1973;28:96-102.
20. Norrell H, Wilson CB, Slagel DE, Clark DB: Leukoencephalopathy following the administration of methotrexate into the cerebrospinal fluid in the treatment of primary brain tumors. Cancer 1974;33:923-932.
21. Flament-Durand J, Ketelbant-Balasse P, Maurus R, Regnier R, Spehl M: Intracerebral calcifications appearing during the course of acute lymphocytic leukemia treated with methotrexate and X-rays. Cancer 1975;35:319-325.
22. McIntosh S, Fischer DB, Rothman SG, Rosenfield N, Lobel JS, O'Brien R: Intracranial calcifications in childhood leukemia. An association with systemic chemotherapy. J Pediatr 1977;91:909-913.
23. Peylan-Ramu N, Poplack DG, Pizzo PA, Adornato BT, Di Chiro G: Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy. N Engl J Med 1978;298:815-818.
24. Colosimo C, Di Lella GM, Petrone AM, Mastrangelo S, Riccardi R: CNS radiochemoprophylaxis in children with acute lymphoblastic leukemia. Neurotoxicity and diagnostic imaging. Rays 1994;19:511-526.
25. Price RA, Jamieson PA: The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer 1975;35:306-318.
26. Griffin TW, Rasey JS, Bleyer WA: The effect of photon irradiation on blood-brain barrier permeability to methotrexate in mice. Cancer 1977;40:1109.
27. Copeland DR, Dowell RE, Jr, Fletcher JM, Bordeaux JD, Sullivan MP, Jaffe N, et al: Neuropsychological effects of childhood cancer treatment. J Child Neurol 1988;3:53-62.
28. Mulhern RK, Ochs J, Fairclough D, Wasserman AL, Davis KS, Williams JM: Intellectual and academic achievement status after CNS relapse: a retrospective analysis of 40 children treated for acute lymphoblastic leukemia. J Clin Oncol 1987;5:933-940.
29. Mulhern RK, Wasserman AL, Fairclough D, Ochs J: Memory function in disease-free survivors of childhood acute lymphocytic leukemia given CNS prophylaxis with or without 1,800 cGy cranial irradiation. J Clin Oncol 1988;6:315-320.
30. Ochs J, Mulhern R, Fairclough D, Parvey L, Whitaker J, Ch'ien L, et al: Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: A prospective study. J Clin Oncol 1991;9:145-151.
31. Paakko E, Harila-Saari A, Vanionpaa L, Himanen S, Pyhtinen J, Lanning M: White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: Correlation with neuropsychological findings. Med Pediatr Oncol 2000;35:456-461.
32. Van Gool SW, Van Kerschaver E, Brock P, Pottel H, Hulstaert F, Vanmechelen E, et al: Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. Leukemia 2000; 14:2076-2084.
33. Davidson A, Payne G, Leach MO, McVicar D, Britton JM, Watson M, et al: Proton magnetic resonance spectroscopy ((1)H-MRS) of the brain following high-dose methotrexate treatment for childhood cancer. Med Pediatr Oncol 2000;35:28-34.
34. Harila-Saari AH, Huuskonen UE, Tolonen U, Vainionpaa LK, Lanning BM: Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: A study with motor evoked potentials. Med Pediatr Oncol 2001;36:345-351.
35. Ettinger LJ: Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 1982;50:444-450.
36. Lee AC, Wong KW, Fong KW, So KT: Intrathecal methotrexate overdose. Acta Paediatr 1997;86:434-437.
37. Weller M, Marini AM, Finiels-Marlier F, Martin B, Paul SM: MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate. Eur J Pharmacol 1993;248:303-312.
38. Gregorios JB, Gregorios AB, Mora J, Marcillo A, Fojaco RM, Green B: Morphologic alterations in rat brain following systemic and intra-ventricular methotrexate injection: Light and electron microscopic studies. J Neuropathol Exp Neurol 1989;48:33-47.
39. Gilbert MR, Harding BL, Grossman SA: Methotrexate neurotoxicity: In vitro studies using cerebellar explants from rats. Cancer Res 1989;49:2502-2505.
40. Bruce-Gregorios JH, Agarwal RP, Oracion A, Ramirez A, Lin L: Effects of methotrexate on RNA and purine synthesis of astrocytes in primary culture. J Neuropathol Exp Neurol 1991;50:770-778.
41. Covey JM: Polyglutamate derivatives of folic acid coenzymes and methotrexate. Life Sci 1980;26:665-678.
42. Galivan J: Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. 7. Mol Pharmacol 1980;17:105-110.
43. Fry DW, Yalowich JC, Goldman ID: Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem 1982;257:1890-1896.
44. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J: Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985;260:9720-9726.
45. McGuire JJ, Hsieh P, Coward JK, Bertino JR: Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. J Biol Chem 1980;255:5776-5788.
46. McKeever MP, Weir DG, Molloy A., Scott JM: Betaine-homocysteine methyltransferase: Organ distribution in man, pig and rat and subcellular distribution in the rat. Clin Sci (Lond) 1991;81:551-556.
47. Thompson GA, Kilpatrick IC: The neurotransmitter candidature of sulphur-containing excitatory amino acids in the mammalian central nervous system. Pharmacol Ther 1996;72:25-36.
48. Curtis D, Watkins J: Acidic amino acids with strong excitatory actions on mammalian neurones. J Physiol 1963;166:1-14.
49. Allegra CJ, Drake JC, Jolivet J, Chabner BA: Inhibition of phosphoribosylaminoimidazole-carboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985;82:4881-4885.
50. Baggott J, Vaughn W, Hudson B: Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236:193-200.
51. Craine J, Hall E, Kaufman S: The isolation and characterization of dihydropteridine reductase from sheep liver. J Biol Chem 1972;247:6082-6091.
52. Surtees R, Clelland J, Hann I: Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. J Clin Oncol 1998;16:1505-1511.
53. Lambie DG, Johnson RH: Drugs and folate metabolism. Drugs 1985;30:145-155.
54. Kishi T, Kawamura I, Harada Y, Eguchi T, Sakura N, Ueda K, et al: Effect of betaine on S-adenosylmethionine levels in the cerebrospinal fluid in a patient with methylenetetrahy-drofolate reductase deficiency and peripheral neuropathy. J Inherit Metab Dis 1994;17:560-565.
55. Surtees R, Leonard J, Austin S: Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet 1991;338:1550-1554.
56. Hyland K, Smith I, Bottiglieri T, Perry J, Wendel U, Clayton PT, et al: Demyelination and decreased S-adenosylmethionine in 5,10-methylenetetrahydrofolate reductase deficiency. Neurology 1988;38:459-462.
57. 6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.
58. Sydow K, Boger RH: Homocysteine, endothelial dysfunction and cardiovascular risk: Pathomechanisms and therapeutic options. Z Kardiol 2001;90:1-11.
59. Bottiglieri T, Hyland K: S-adenosylmethionine levels in psychiatric and neurological disorders: A review. Acta Neurol Scand Suppl 1994;154:19-26.
60. Reynolds EH, Godfrey P, Bottiglieri T, Toone BK, Carney MWP: S-adenosylmethionine and Alzheimer's disease. Neurology 1989;39 (suppl 1):397.
61. Carrieri PB, Indaco A, Gentile S, Troisi E, Campanella G: S-adenosylmethionine treatment of depression in patients with Parkinson's disease: A double blind, crossover study versus placebo. Curr Ther Res 1990;48:154-160.
62. Keating JN, Trimble KC, Mulcahy F, Scott JM, Weir DG: Evidence of brain methyltransferase inhibition and early brain involvement in HIV-positive patients. Lancet 1991;337:935-939.
63. Kishi T, Tanaka Y, Ueda K: Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy. Cancer 2000;89:925-931.
64. Brattstrom LE, Hardebo JE, Hultberg BL: Moderate homocysteinemia - a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 1984;15:1012-1016.
65. Genest JJ, Jr, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR: Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990;16:1114-1119.
66. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P: Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990;21:572-576.
67. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-1398.
68. Watkins D, Rosenblatt DS: Functional methio-nine synthase deficiency (cblE and cblG): Clinical and biochemical heterogeneity. Am J Med Genet 1989;34:427-434.
69. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155.
70. Grieco AJ: Homocystinuria: Pathogenetic mechanisms. Am J Med Sci 1977;273:120-132.
71. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-6373.
72. Chambers JC, McGregor A, Jean-Marie J, Kooner JS: Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998;351:36-37.
73. Wall RT, Harlan JM, Harker LA, Striker GE: Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury. Thromb Res 1980;18:113-121.
74. Ling Q, Hajjar KA: Inhibition of endothelial cell thromboresistance by homocysteine. J Nutr 2000;130(suppl):373S-376S.
75. Rodgers GM, Kane WH: Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;77:1909-1916.
76. Hayashi T, Honda G, Suzuki K: An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992;79:2930-2936.
77. Preibisch G, Kuffner C, Elstner EF: Biochemical model reactions on the prooxidative activity of homocysteine. Z Naturforsch [C] 1993;48:58-62.
78. Broxson EH, Jr, Stork LC, Allen RH, Stabler SP, Kolhouse JF: Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. Cancer Res 1989;49:5879-5883.
79. Refsum H, Ueland PM, Kvinnsland S: Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res 1986;46:5385-5391.
80. Refsum H, Helland S, Ueland PM: Fasting plasma homocysteine as a sensitive parameter of antifolate effect: A study of psoriasis patients receiving low-dose methotrexate treatment. Clin Pharmacol Ther 1989;46:510-520.
81. Refsum H, Wesenberg F, Ueland PM: Plasma homocysteine in children with acute lymphoblastic leukemia: Changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51:828-835.
82. Quinn CT, Griener JC, Bottiglieri T, Hyland K, Farrow A, Kamen BA: Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 1997;15:2800-2806.
83. Quinn CT, Griener JC, Bottiglieri T, Kamen BA: Methotrexate, homocysteine, and seizures. J Clin Oncol 1998;16:393-394.
84. Packer RJ, Grossman RI, Belasco JB: High dose systemic methotrexate-associated acute neurologic dysfunction. Med Pediatr Oncol 1983;11:159-161.
85. Flott-Rahmel B, Schurmann M, Schluff P, Fingerhut R, Musshoff U, Fowler B, et al: Homocysteic and homocysteine sulphinic acid exhibit excitotoxicity in organotypic cultures from rat brain. Eur J Pediatr 1998;157 (suppl 2):S112-S117.
86. Omori S, Kodama H, Ikegami T, Mizuhara S, Oura T: Unusual sulfur-containing amino acids in the urine of homocystinuric patients: III. Homocysteic acid, homocysteine sulfinic acid, S-(carboxymethylthio) homocysteine, and S-(3-hydroxy-3-carboxy-n-propyl). Physiol Chem Phys 1972;4:286-294.
87. Baba A, Yamagami S, Mizuo H, Iwata H: Microassay of cysteine sulfinic acid by an enzymatic cycling method. Anal Biochem 1980;101:288-293.
88. Pullan LM, Olney JW, Price MT, Compton RP, Hood WF, Michel J, et al: Excitatory amino acid receptor potency and subclass specificity of sulfur-containing amino acids. J Neurochem 1987;49:1301-1307.
89. Curras MC, Dingledine R: Selectivity of amino acid transmitters acting at N-methyl-D-aspartate and amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors. Mol Pharmacol 1992;41:520-526.
90. Choi DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634.
91. Folbergrova J, Haugvicova R, Mares P: Behavioral and metabolic changes in immature rats during seizures induced by homocysteic acid: The protective effect of NMDA and non-NMDA receptor antagonists. Exp Neurol 2000;161:336-345.
92. Turski WA: Homocysteic acid: Convulsant action of stereoisomers in mice. Brain Res 1989;479:371-373.
93. Lipton SA, Rosenberg PA: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622.
94. Meldrum B, Garthwaite J: Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990;11:379-387.
95. Bridges RJ, Hatalski CG, Shim SN, Cummings BJ, Vijayan V, Kundi, A et al: Gliotoxic actions of excitatory amino acids. Neuropharmacology 1992;31:899-907.
96. 3H]aspartate from cultured cerebellar granule cells: The role of glutamate receptor activation coupled to reversal of the acidic amino acid plasma membrane carrier. Neuroscience 1992;50:107-115.
97. Croucher MJ, Thomas LS, Ahmadi H, Lawrence V, Harris JR: Endogenous sulphur-containing amino acids: Potent agonists at presynaptic metabotropic glutamate autoreceptors in the rat central nervous system. Br J Pharmacol 2001;133:815-824.
98. Cox DW, Headley MH, Watkins JC: Actions of L- and D-homocysteate in rat CNS: A correlation between low- affinity uptake and the time courses of excitation by microelectrophoretically applied L-glutamate analogues. J Neurochem 1977;29:579-588.
99. Grieve A, Butcher SP, Griffiths R: Synapto-somal plasma membrane transport of excitatory sulphur amino acid transmitter candidates: Kinetic characterisation and analysis of carrier specificity. J Neurosci Res 1992;32:60-68.
100. Griffiths R: Cysteine sulphinate (CSA) as an excitatory amino acid transmitter candidate in the mammalian central nervous system. Prog Neurobiol 1990;35:313-323.
101. Griffiths R: The biochemistry and pharmacology of excitatory sulphur-containing amino acids. Biochem Soc Trans 1993;21:66-72.
102. Recasens M, Varga V, Nanopoulos D, Saa-doun F, Vincendon G, Benavides J: Evidence for cysteine sulfinate as a neurotransmitter. Brain Res 1982;239:153-173.
103. Bruce-Gregorios JH, Soucy DM, Chen MG, Norenberg MD: Effect of methotrexate on glial fibrillary acidic protein content of astrocytes in primary culture. J Neuropathol Exp Neurol 1991;50:118-125.
104. Gregorios JB, Soucy D: Effects of methotrexate on astrocytes in primary culture: Light and electron microscopic studies. Brain Res 1990;516:20-30.
105. Stark H, Reichert U, Grassmann S: Structure, function and potential therapeutic possibilities of NMDA receptors. 2. Therapy concepts and new receptor ligands. Pharm Unserer Zeit 2000;29:228-236.
106. Saransaari P, Oja SS: Taurine and neural cell damage. Amino Acids 2000;19:509-526.
107. Quinn CT, Griener JC, Bottiglieri T, Hyland K, Farrow A, Kamen BA: Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 1997;15:2800-2806.
108. Quinn CT, Griener JC, Bottiglieri T, Kamen BA: Methotrexate, homocysteine, and seizures. J Clin Oncol 1998;16:393-394.
109. Drachtman RA, Cole PD, Golden CB, James SJ, Melnyk S, Aisner J et al: Dextromethor-phan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002;19:319-327.
110. Kane BJ, Kuhn JG, Roush MK: Pentostatin: An adenosine deaminase inhibitor for the treatment of hairy cell leukemia. Ann Pharmacother 1992;26:939-947.
111. Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-2682.
112. Bernini JC, Fort DW, Griener JC, Kane BJ, Chappell WB, Kamen BA: Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995;345:544-547.
113. Peyriere H, Poiree M, Cociglio M, Margue-ritte G, Hansel S, Hillaire-Buys D: Reversal of neurologic disturbances related to high-dose methotrexate by aminophylline. Med Pediatr Oncol 2001;36:662-664.
114. Smith I, Howells DW, Hyland K: Pteridines and mono-amines: Relevance to neurological damage. Postgrad Med J 1986;62:113-123.
115. Smith I, Clayton BE, Wolff OH: Letter: A variant of phenylketonuria. Lancet 1975;1:328-329.
116. Abelson HT: Methotrexate and central nervous system toxicity. Cancer Treat Rep 1978;62:1999-2001.
117. Millot F, Dhondt JL, Hayte JM, Bauters F: Impairment of cerebral biogenic amine synthesis in a patient receiving high-dose methotrexate. Am J Pediatr Hematol Oncol 1992;14:276-278.
118. Millot F, Chastagner P, Dhondt J, Sommelet D: Substitutive therapy in a case of methotrexate neurotoxicity (letter). Eur J Cancer 1992;28A:1935.
119. Blau N, Curtius AC, Kierat L, Leupold D, Kohne E: Hyperphenylalaninemia caused by dihydropteridine reductase deficiency in children receiving chemotherapy for acute lymphoblastic leukemia (letter). J Pediatr 1989;115:661-663.
120. Culvenor AJ, Miller LP, Levine RA, Lovenberg W: Effects of methotrexate on biopterin levels and synthesis in rat cultured pineal glands. J Neurochem 1984;42:1707-1714.
121. Duch DS, Lee CL, Edelstein MP, Nichol CA: Biosynthesis of tetrahydrobiopterin in the presence of dihydrofolate reductase inhibitors. Mol Pharmacol 1983;24:103-108.
122. 2 intravenous methotrexate. Pediatr Res 1995;37:151-154.
123. Silverstein FS, Hutchinson RJ, Johnston MV: Cerebrospinal fluid biogenic amine metabolites in children during treatment for acute lymphocytic leukemia. Pediatr Res 1986;20:285-291.
124. Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N et al: Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - A Pediatric Oncology Group study. J Clin Oncol 1998;16:1712-1722.
125. Crellin R, Bottiglieri T, Reynolds EH: Folates and psychiatric disorders. Clinical potential. Drugs 1993;45:623-636.
126. Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH: Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53:1096-1098.
127. Smolin LA, Benevenga NJ, Berlow S: The use of betaine for the treatment of homocystinuria. J Pediatr 1981;99:467-472.
128. van Guldener C, Stehouwer CD: Homocysteine-lowering treatment: An overview. Expert Opin Pharmacother 2001;2:1449-1460.
129. Eisberg S, Tillmann W: Enzephalopathie unter systemischer Hochdosismethotrexattherapie bei akuter lymphoblastischer Leukämie. Monatschr Kinderheilkd 2000;148:13-17.
130. Lipton SA: Calcium channel antagonists in the prevention of neurotoxicity. Adv Pharmacol 1991;22:271-297.